What is Serán?
Serán operates at the forefront of pharmaceutical development, employing a science-first methodology and advanced technologies to empower its healthcare clientele. The company's core mission is to accelerate the discovery and development of novel medicines, ultimately aiming to enhance patient health outcomes. This focus positions Serán as a critical enabler within the life sciences ecosystem, facilitating breakthroughs in therapeutic areas.
How much funding has Serán raised?
Serán has raised a total of $200.3M across 2 funding rounds:
Debt
$350K
Other Financing Round
$200M
Debt (2020): $350K with participation from PPP
Other Financing Round (2024): $200M led by Vivo Capital and Bain Capital
Key Investors in Serán
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
Bain Capital
Founded in 1984, Bain Capital is one of the world's leading private investment firms, committed to creating lasting impact through a global platform that invests across private equity, growth & venture, capital solutions, credit & capital markets, and real assets.
PPP
Public-Private Partnership
What's next for Serán?
With the recent major strategic investment, Serán is poised for accelerated expansion and further innovation in drug discovery. The substantial capital infusion is expected to fuel research and development initiatives, potentially leading to the advancement of its pipeline and the forging of new partnerships within the healthcare industry. This strategic backing signals strong confidence from investors in Serán's scientific approach and its potential to deliver impactful medical solutions.
See full Serán company page
